Projects per year
Personal profile
Education
- 2006-2012 Ph.D., Department of Pharmacy, National Taiwan University
- 2005-2006 M.S., Department of Pharmacy, National Taiwan University
- 2000-2005 B.S., Department of Pharmacy, National Taiwan University
Experience
- 2016.03- Assistant Professor, School of Pharmacy, Taipei Medical University
- 2016.01-2016.03 Postdoctoral Research Fellow, Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
- 2013.07-2014.02 Postdoctoral Research Scholar, Academia Sinica
- 2012.02-2013.06 Postdoctoral Research Fellow, National Taiwan University
Awards
- 2019 Young Researcher Award, Taipei Medical University
Research Interests
- 藥理及毒理
- 藥學
Fingerprint Dive into the research topics where Chun-Han Chen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 10 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
Using Transcriptomic and Proteomic Approaches to Investigate the Molecular Mechanisms of Platinum-Resistance in Bladder Cancer and Develop New Therapeutic Strategies
8/1/19 → 7/31/20
Project: A - Government Institution › b - Ministry of Science and Technology
探討CK1 delta在膀胱癌進展的角色，並以其為治療標的之新藥研發。
8/1/18 → 7/1/19
Project: A - Government Institution › b - Ministry of Science and Technology
PIK3C3抑制劑對於膀胱癌的治療效果與機轉探討
8/1/17 → 7/31/18
Project: A - Government Institution › b - Ministry of Science and Technology
Targeting Class III Phosphoinositide 3-Kinase (Pi3k) for Anticancer Drug Discovery
8/1/16 → 7/31/17
Project: A - Government Institution › b - Ministry of Science and Technology
Research Output
CK1δ as a potential therapeutic target to treat bladder cancer
Lin, Y. C., Chen, M. C., Hsieh, T. H., Liou, J. P. & Chen, C. H., Apr 15 2020, In : Aging. 12, 7, p. 5764-5780 17 p.Research output: Contribution to journal › Article
Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., Jun 15 2020, In : European Journal of Medicinal Chemistry. 196, 112329.Research output: Contribution to journal › Comment/debate
Open Access
Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))
Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., Aug 1 2020, In : European Journal of Medicinal Chemistry. 199, 112406.Research output: Contribution to journal › Comment/debate
Open Access
Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., Apr 15 2020, In : European Journal of Medicinal Chemistry. 192, p. 112158 112158.Research output: Contribution to journal › Article
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., Mar 15 2020, In : European Journal of Medicinal Chemistry. 190, 112086.Research output: Contribution to journal › Article